Domchek SM, Postel-Vinay S, Im SA, Park YH, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 2020 Aug 6. pii: S1470-2045(20)30324.
PMID: 32771088